Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842802 | 0.87 | PTGER4 (0.43) | KDM4EALDH1A1SMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL26908087 | 0.85 | HSP90B1 (0.34) | ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL1842830 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL12549925 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL25366601 | 0.79 | BACE1 (0.38) | ALDH1A1SMN1; SMN2MAPTPTGER3 | |
| SCHEMBL30557730 | 0.79 | BACE1 (0.38) | ALDH1A1SMN1; SMN2MAPTPTGER3 | |
| SCHEMBL32684712 | 0.79 | PTGER4 (0.40) | KDM4EALDH1A1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL1847633 | 0.78 | PTGER4 (0.47) | PTGER4PTGDRMAPTTBXA2RPTGER1 | |
| SCHEMBL32684965 | 0.78 | PTGER4 (0.40) | KDM4EALDH1A1KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL1842923 | 0.77 | KCNQ3 (0.38) | KDM4EALDH1A1SMN1; SMN2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | disclosed |
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| EP-2320906-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Beta Pharma Canada Inc. (CA) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | KDM4E 1395/4885ALDH1A1 997/4885CISD2 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.